An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort - ScienceDirect
Por um escritor misterioso
Descrição
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data - The Lancet Oncology
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation
Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study - eClinicalMedicine
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors - ScienceDirect
Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study - European Urology Focus
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study - The Lancet Digital Health
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations - The Lancet Haematology
Baseline Health-related Quality of Life Predicts Bladder Cancer–specific Survival Following Radical Cystectomy - European Urology Focus
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study - The Lancet Oncology
de
por adulto (o preço varia de acordo com o tamanho do grupo)
